Patent intelligence · US
US 6022861
Ketoheterocyclic inhibitors of factor Xa
Ketoheterocyclic inhibitors of factor Xa
Patent details — US 6022861
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 8, 2000
- Expiration
- Feb 3, 2020
- Applicant
- COR Therapeutics, Inc.
- Claims
- 45
- CPC classes
- A61K, A61K38/00
Quick answer
US 6022861 (Ketoheterocyclic inhibitors of factor Xa) is held by COR Therapeutics, Inc.. Status: expired. Granted Feb 8, 2000. Expires Feb 3, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- COR Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 45
- CPC classes
- A61K, A61K38/00
More from COR Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11759482
Methods and compositions for treating skeletal muscular dystrophy
granted -
US 10695293
Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
granted -
US 10369173
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9884076
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9623085
Chimeric natriuretic peptide compositions and methods of preparation
granted -
US 9616107
Therapy for kidney disease and/or heart failure
granted -
US 9314507
Methods of treatment of heart failure with natriuretic peptides
granted
Frequently asked questions
What is US patent 6022861?
US 6022861 (Ketoheterocyclic inhibitors of factor Xa) is held by COR Therapeutics, Inc.. Status: expired. Granted Feb 8, 2000. Expires Feb 3, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6022861?
COR Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 43 pharmaceutical patents for this assignee.
When does US 6022861 expire?
Our index shows an expiration date of Feb 3, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.